Treatment for alcohol use disorder among persons with and without HIV in a clinical care setting in the United States.

[1]  K. Donoghue.  The correlates and extent of prescribing of medications for alcohol relapse prevention in England. , 2021, Addiction.

[2]  M. Rothberg,et al.  Characterizing the Variation of Alcohol Cessation Pharmacotherapy in Primary Care , 2021, Journal of General Internal Medicine.

[3]  J. Leung,et al.  Treatment rates for alcohol use disorders: a systematic review and meta-analysis. , 2020, Addiction.

[4]  C. B. Hare,et al.  Health System-Based Unhealthy Alcohol Use Screening and Treatment Comparing Demographically-Matched Participants With and Without HIV. , 2020, Alcoholism, clinical and experimental research.

[5]  Charles E. Leonard,et al.  National outpatient medication utilization for opioid and alcohol use disorders from 2014 to 2016. , 2020, Journal of substance abuse treatment.

[6]  K. Kraemer,et al.  Impact of behavioral and medication treatment for alcohol use disorder on changes in HIV-related outcomes among patients with HIV: A longitudinal analysis. , 2020, Drug and alcohol dependence.

[7]  S. Normand,et al.  Medication Utilization for Alcohol Use Disorder in a Commercially Insured Population , 2020, Journal of General Internal Medicine.

[8]  Jessica A. Chen,et al.  Racial/ethnic and gender differences in receipt of brief intervention among patients with unhealthy alcohol use in the U.S. Veterans Health Administration. , 2020, Journal of substance abuse treatment.

[9]  B. Kagan,et al.  Effect of Screening, Brief Intervention and Referral to Treatment for Unhealthy Alcohol and Other Drug Use in Mental Health Treatment Settings: A Randomised Controlled Trial. , 2020, Addiction.

[10]  F. Altice,et al.  Safety of oral naltrexone in HIV-positive men who have sex with men and transgender women with alcohol use disorder and initiating antiretroviral therapy , 2020, PloS one.

[11]  Gina A. Keppel,et al.  Prevalence of documented alcohol and opioid use disorder diagnoses and treatments in a regional primary care practice-based research network. , 2020, Journal of substance abuse treatment.

[12]  Brandon D. L. Marshall,et al.  Predictors of initiation of and retention on medications for alcohol use disorder among people living with and without HIV. , 2020, Journal of substance abuse treatment.

[13]  M. Horberg,et al.  Changes in Days of Unhealthy Alcohol Use and Antiretroviral Therapy Adherence, HIV RNA Levels, and Condomless Sex: A Secondary Analysis of Clinical Trial Data , 2019, AIDS and Behavior.

[14]  P. Volberding,et al.  Implementing electronic substance use disorder and depression and anxiety screening and behavioral interventions in primary care clinics serving people with HIV: Protocol for the promoting access to care engagement (PACE) trial. , 2019, Contemporary clinical trials.

[15]  J. Dziura,et al.  Integrated stepped alcohol treatment for patients with HIV and alcohol use disorder: a randomised controlled trial. , 2019, The lancet. HIV.

[16]  K. Kraemer,et al.  Low levels of initiation, engagement, and retention in substance use disorder treatment including pharmacotherapy among HIV-infected and uninfected veterans. , 2019, Journal of substance abuse treatment.

[17]  Richard D Moore,et al.  Recent Substance Use and Probability of Unsuppressed HIV Viral Load among Persons on Antiretroviral Therapy in Continuity Care. , 2019, American journal of epidemiology.

[18]  P. Volberding,et al.  Interventions to Reduce Unhealthy Alcohol Use among Primary Care Patients with HIV: the Health and Motivation Randomized Clinical Trial , 2019, Journal of General Internal Medicine.

[19]  R. Cook,et al.  HIV care provider perceptions and approaches to managing unhealthy alcohol use in primary HIV care settings: a qualitative study , 2019, Addiction Science & Clinical Practice.

[20]  M. Horberg,et al.  Healthcare Effectiveness Data and Information Set (HEDIS) measures of alcohol and drug treatment initiation and engagement among people living with the human immunodeficiency virus (HIV) and patients without an HIV diagnosis , 2019, Substance abuse.

[21]  D. McCarty,et al.  Factors Associated with Healthcare Effectiveness Data and Information Set (Hedis) Alcohol and Other Drug Measure Performance in 2014–2015 , 2019, Substance abuse.

[22]  C. Rentsch,et al.  Association Between Gabapentin Receipt for Any Indication and Alcohol Use Disorders Identification Test—Consumption Scores Among Clinical Subpopulations With and Without Alcohol Use Disorder , 2019, Alcoholism, clinical and experimental research.

[23]  E. Williams,et al.  Influence of comorbid drug use disorder on receipt of evidence-based treatment for alcohol use disorder among VA patients with alcohol use disorder and Hepatitis C and/or HIV. , 2019, Drug and alcohol dependence.

[24]  B. Lau,et al.  Alcohol Use Patterns and Subsequent Sexual Behaviors Among Women, Men who have Sex with Men and Men who have Sex with Women Engaged in Routine HIV Care in the United States , 2018, AIDS and Behavior.

[25]  Chyke A Doubeni,et al.  Screening and Behavioral Counseling Interventions to Reduce Unhealthy Alcohol Use in Adolescents and Adults: US Preventive Services Task Force Recommendation Statement , 2018, JAMA.

[26]  Mardge H. Cohen,et al.  Longitudinal associations between food insecurity and substance use in a cohort of women with or at risk for HIV in the United States , 2018, Addiction.

[27]  H. Kranzler,et al.  Diagnosis and Pharmacotherapy of Alcohol Use Disorder: A Review , 2018, JAMA.

[28]  L. Fiellin,et al.  Efficacy of Extended-Release Naltrexone on HIV-Related and Drinking Outcomes Among HIV-Positive Patients: A Randomized-Controlled Trial , 2018, AIDS and Behavior.

[29]  L. Ray,et al.  Barriers to initiation of extended release naltrexone among HIV-infected adults with alcohol use disorders. , 2018, Journal of substance abuse treatment.

[30]  J. Yager,et al.  The American Psychiatric Association Practice Guideline for the Pharmacological Treatment of Patients With Alcohol Use Disorder. , 2018, The American journal of psychiatry.

[31]  P. Korthuis,et al.  Feasibility and safety of extended‐release naltrexone treatment of opioid and alcohol use disorder in HIV clinics: a pilot/feasibility randomized trial , 2017, Addiction.

[32]  S. Shortreed,et al.  Among patients with unhealthy alcohol use, those with HIV are less likely than those without to receive evidence-based alcohol-related care: A national VA study. , 2017, Drug and alcohol dependence.

[33]  M. Mugavero,et al.  Prevalence and Predictors of Substance Use Disorders Among HIV Care Enrollees in the United States , 2017, AIDS and Behavior.

[34]  B. Lau,et al.  Prevalence and Factors Associated with Hazardous Alcohol Use Among Persons Living with HIV Across the US in the Current Era of Antiretroviral Treatment , 2017, AIDS and Behavior.

[35]  Richard D Moore,et al.  Heavy Alcohol Use Is Associated With Worse Retention in HIV Care , 2016, Journal of acquired immune deficiency syndromes.

[36]  Richard D Moore,et al.  Risk of End-Stage Liver Disease in HIV-Viral Hepatitis Coinfected Persons in North America From the Early to Modern Antiretroviral Therapy Eras. , 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[37]  D. Welsh,et al.  Presence of an Alcohol Use Disorder is Associated with Greater Pneumonia Severity in Hospitalized HIV-Infected Patients , 2016, Lung.

[38]  Brandon D. L. Marshall,et al.  Risk of mortality and physiologic injury evident with lower alcohol exposure among HIV infected compared with uninfected men. , 2016, Drug and alcohol dependence.

[39]  K. Crothers,et al.  Prevalence of non-HIV cancer risk factors in persons living with HIV/AIDS: a meta-analysis , 2016, AIDS.

[40]  F. Naudet,et al.  Risks and Benefits of Nalmefene in the Treatment of Adult Alcohol Dependence: A Systematic Literature Review and Meta-Analysis of Published and Unpublished Double-Blind Randomized Controlled Trials , 2015, PLoS medicine.

[41]  B. Grant,et al.  Epidemiology of DSM-5 Alcohol Use Disorder: Results From the National Epidemiologic Survey on Alcohol and Related Conditions III. , 2015, JAMA psychiatry.

[42]  Tyrel J. Starks,et al.  Patterns of substance use among HIV-positive adults over 50: implications for treatment and medication adherence. , 2014, Drug and alcohol dependence.

[43]  S. Armeli,et al.  Topiramate treatment for heavy drinkers: moderation by a GRIK1 polymorphism. , 2014, The American journal of psychiatry.

[44]  C. Quesenberry,et al.  Factors associated with treatment initiation for psychiatric and substance use disorders among persons with HIV. , 2013, Psychiatric services.

[45]  K. Humphreys,et al.  Meta-analysis of naltrexone and acamprosate for treating alcohol use disorders: when are these medications most helpful? , 2013, Addiction.

[46]  Alex H. S. Harris,et al.  Pharmacotherapy of alcohol use disorders by the Veterans Health Administration: patterns of receipt and persistence. , 2012, Psychiatric services.

[47]  E. Walker,et al.  Diagnostic and Statistical Manual of Mental Disorders , 2013 .

[48]  R. D. Bruce,et al.  HIV Treatment Outcomes Among HIV-Infected, Opioid-Dependent Patients Receiving Buprenorphine/Naloxone Treatment within HIV Clinical Care Settings: Results From a Multisite Study , 2011, Journal of acquired immune deficiency syndromes.

[49]  R. Finkelstein,et al.  Patient Perspectives on Buprenorphine/Naloxone Treatment in the Context of HIV Care , 2011, Journal of acquired immune deficiency syndromes.

[50]  C. Quesenberry,et al.  Excess mortality among HIV-infected patients diagnosed with substance use dependence or abuse receiving care in a fully integrated medical care program. , 2011, Alcoholism, clinical and experimental research.

[51]  Bruce G. Link,et al.  Stigma and treatment for alcohol disorders in the United States. , 2010, American journal of epidemiology.

[52]  K. Kraemer,et al.  The Association Between Alcohol Consumption and Prevalent Cardiovascular Diseases Among HIV-Infected and HIV-Uninfected Men , 2010, Journal of acquired immune deficiency syndromes.

[53]  Jessica G. Burke,et al.  The Development of a Standardized Neighborhood Deprivation Index , 2006, Journal of Urban Health.

[54]  B. Oldfield,et al.  Integration of care for HIV and opioid use disorder. , 2019, AIDS.

[55]  Teresa Y. Lin,et al.  The Kaiser Permanente Northern California Adult Member Health Survey. , 2016, The Permanente journal.

[56]  S. Quello,et al.  Gabapentin treatment for alcohol dependence: a randomized clinical trial. , 2014, JAMA internal medicine.